Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
34.2M
-
Shares change
-
-800K
-
Total reported value, excl. options
-
$1.05B
-
Value change
-
-$32.7M
-
Put/Call ratio
-
0.45
-
Number of buys
-
72
-
Number of sells
-
-41
-
Price
-
$30.80
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q1 2018
149 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2018.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.2M shares
of 105M outstanding shares and own 32.69% of the company stock.
Largest 10 shareholders include Essex Woodlands Management, Inc. (3.84M shares), WELLINGTON MANAGEMENT GROUP LLP (3.81M shares), JPMORGAN CHASE & CO (3.44M shares), FRANKLIN RESOURCES INC (3.17M shares), BlackRock Inc. (2.41M shares), Bank of New York Mellon Corp (2.01M shares), ArrowMark Colorado Holdings LLC (1.74M shares), NovaQuest Capital Management, L.L.C. (1.56M shares), MILLENNIUM MANAGEMENT LLC (1.49M shares), and JENNISON ASSOCIATES LLC (1.48M shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.